Long-term Follow-up of Subfoveal Neovascular AMD

Medical University of Vienna70 enrolled

Overview

Treatment naive patients with subfoveal nAMD initially treated monthly with intravitreal anti-VEGF and subsequently PRN, will be included in this study. Patients will be investigated for the first 2 years monthly and subsequently according to disease activity but at least every two months. Patients will be examined with 4m BCVA ETDRS distance visual acuity, reading acuity measured by Radner-Reading-Charts, contrast sensitivity by Pelli-Robson score, microperimetry and HD-OCT.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Exudative Age-related Macular Degeneration

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * treatment naive subfoveal AMD, written informed consent, able to read Exclusion Criteria: * choroidal neovascularisation due to other ocular diseases, mature cataract

Locations (1)

Department of Ophthalmology Medical University of Vienna

Vienna, State of Vienna, Austria

RECRUITING

Outcomes

Primary Outcomes

Long-term visual function performance

Time frame: four years

Secondary Outcomes

change of morphological alterations assessed by SD-OCT

Time frame: four years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.